FBIO - Fortress Biotech, Inc.
| Previous Close | 1.6600 |
| Open | 1.6700 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 2200 |
| Day's Range | 1.5000 - 1.6900 |
| 52 Week Range | 0.4900 - 3.3800 |
| Volume | 475,196 |
| Avg. Volume | 740,293 |
| Market Cap | 98.498M |
| Beta (3Y Monthly) | 4.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3800 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- GlobeNewswire•24 days ago
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its second pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 24 hours (SPID24) compared to placebo in patients with postoperative pain following abdominoplasty surgery. In addition, the trial met all of its key secondary endpoints.
- GlobeNewswire•last month
Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019
NEW YORK, and MEMPHIS, Tenn., May 23, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical.
- Zacks•last month
Will Fortress Biotech to Surge Higher?
As of late, it has definitely been a great time to be an investor Fortress Biotech.
- GlobeNewswire•last month
Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
NEW YORK and COLUMBUS, Ohio, May 16, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical.
- GlobeNewswire•last month
Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019
NEW YORK, May 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
- GlobeNewswire•last month
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, May 13, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
- Associated Press•2 months ago
Fortress Biotech: 1Q Earnings Snapshot
The New York-based company said it had net income of 2 cents per share. Losses, adjusted for non-recurring gains, came to 27 cents per share. The biopharmaceutical company posted revenue of $6.5 million ...
- GlobeNewswire•2 months ago
Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, May 10, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.
- GlobeNewswire•2 months ago
Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, May 09, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,.
- GlobeNewswire•2 months ago
Mustang Bio Announces Full Exercise of Option
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the underwriters of its recent public offering of common stock have exercised in full their option and purchased an additional 1,031,250 shares at the public offering price of $4.00 per share.
- GlobeNewswire•2 months ago
Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has begun enrolling patients with relapsed or treatment-resistant multiple myeloma in an innovative CS1 chimeric antigen receptor (CAR) T cell therapy (MB-104) trial.
- GlobeNewswire•2 months ago
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing.
- GlobeNewswire•2 months ago
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors. “Tom’s breadth and depth of operational and commercial experience, which includes leadership in the acute care pharmaceutical business, will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman.
- GlobeNewswire•2 months ago
Mustang Bio Announces Proposed Public Offering of Common Stock
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Mustang expects to grant the underwriters a 30‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.
- Simply Wall St.•2 months ago
What Kind Of Shareholders Own Fortress Biotech, Inc. (NASDAQ:FBIO)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Fortress Biotech, Inc. (NASDAQ:FBIO) should be aware of the most powerful sharehold...
- InvestorPlace•2 months ago
Is Mustang Bio the Next Great Biotech Stock?
Do you remember the movie The Boy in the Plastic Bubble starring John Travolta? How about Bubble Boy starring Jake Gyllenhaal? Both were about a child born without an immune system, forced to live in a bubble to avoid contamination from the outside world.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsWell, now, Mustang Bio (NASDAQ:MBIO) has cured eight infants suffering from the "Bubble Boy" immune disorder, sending MBIO stock up as high as $10.20 in pre-Good Friday trading. The question investors are asking themselves today is whether they should get in on the action before it's too late. FOMO is alive and well and living in this micro-cap biotechnology stock. Why MBIO Stock Is a Good Speculative BetAny time a biotech company comes up with a gene therapy that works, there's bound to be excitement surrounding it. Even better if the infants suffered few, if any, side effects from the experimental gene therapy.Mustang Bio is a 2015 spinoff of Fortress Biotech (NASDAQ:FBIO), a company that is run by Lindsay Rosenwald and Michael Weiss, two serial healthcare entrepreneurs, who've spread lots of bets on small companies like Mustang Bio, of which Fortress owns approximately 38%. * 10 High-Yielding Dividend Stocks That Won't Wilt "While I am a biotech entrepreneur, I am also a 'risk manager,' as we have many shots on goal for such small companies," Rosenwald said in an email. "The more shots on goal, theoretically the less risk there is."However, despite the success of the gene therapy to date, it likely won't file for FDA approval until late 2021 or beyond. In the meantime, it's little to no money in -- 2018 income of $561,000 from interest on its cash on hand -- and $31.2 million in operating expenses, such as research and development, out. So, it's likely to burn through $100 million in operating losses before it even files with the FDA. While this might seem like an argument as to why MBIO stock is not a good speculative bet, it's counter-intuitive. Mustang Bio had cash and short-term investments of $61 million at the end of 2017. At the end of 2018, it was down to $34 million, a reduction of around $29 million, not too far off the operating losses for the year. The company announced on March 29, a $20 million venture debt financing agreement at 9% plus the amount by which the one month LIBOR rate exceeds 2.5%. It's currently at 2.48%. With interest rates stalled and possibly heading lower if a recession rears its ugly head, it looks like Mustang Bio's on the hook for about $1.8 million in interest on the loan.That gets it to $54 million on the balance sheet, close to two years worth of operating losses and into 2021. At that point, should everything about MB-107 remain positive, Mustang Bio will have plenty of financing options to get itself through the next two years, including issuing some more MBIO stock. As speculative biotech plays go, Mustang Bio seems like a good one. Why It's NotWhen it comes to biotech investing, there's no sure thing. The company still needs to confirm the benefits of a handful of patients who've received the experimental gene therapy. Those patients could fail to benefit from MB-107, as the others did. In 2020, Mustang Bio takes over the trial program from St. Jude Children's Research Hospital, which is licensing the gene therapy to the company. It's possible, but unlikely, that something could go wrong from a clinical perspective once the trial is in Mustang Bio's hands. However, CEO Manny Litchman doesn't think so. "The data are extraordinary for every single patient," Litchman said. "It's that compelling nature of the data, in particular for those who don't have a matched sibling donor, that we believe will convince the FDA to do this. Of course, just as in life, we don't always get what we want. The FDA could say no to Mustang Bio and then it's back to the drawing board after more than $150 million in losses. The Bottom Line on Mustang Bio StockI'm not a big believer in investing in money-losing companies. However, as Fortress' Rosenwald said, you've got to take a lot of shots in biotech to be successful. The same goes for biotech investing. * Verizon 5G Launch: 12 Things We Know If you can afford to lose your entire investment, I wouldn't see a problem putting down a small wager on MBIO stock. While you're at it, you might put a small amount in Fortress as well to spread your bets and all that cautionary advice. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Is Mustang Bio the Next Great Biotech Stock? appeared first on InvestorPlace.
- GlobeNewswire•2 months ago
St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the New England Journal of Medicine has published data from St. Jude Children’s Research Hospital (“St. Jude”), the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease.
- GlobeNewswire•3 months ago
Mustang Bio to Present at the World Orphan Drug Congress USA 2019
NEW YORK, April 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.
- GlobeNewswire•3 months ago
Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a $20 million debt financing agreement with Horizon Technology Finance Corporation (HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services and cleantech industries.
- GlobeNewswire•3 months ago
Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 18, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.
- GlobeNewswire•3 months ago
Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 18, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.
- Zacks•3 months ago
All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy
Fortress Biotech (FBIO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•3 months ago
Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference
NEW YORK, March 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen.
- GlobeNewswire•4 months ago
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 12, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
